Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,114,833

« Back to Dashboard

Which drugs does patent 8,114,833 protect, and when does it expire?

Patent 8,114,833 protects OZEMPIC, SAXENDA, and VICTOZA, and is included in three NDAs.

This patent has eighteen patent family members in ten countries.

Summary for Patent: 8,114,833

Title:	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Abstract:	The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.
Inventor(s):	Pedersen; Tina Bjeldskov (Smorum, DK), Bonde; Claude (Lyngby, DK), Engelund; Dorthe Kot (Holte, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	11/435,977
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,114,833
Patent Claim Types: see list of patent claims	Formulation; Compound; Use; Device;

Drugs Protected by US Patent 8,114,833

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Novo Nordisk Inc	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Novo Nordisk Inc	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Novo Nordisk Inc	VICTOZA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Foreign Priority and PCT Information for Patent: 8,114,833

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	2003 01719	Nov 20, 2003

International Family Members for US Patent 8,114,833

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004290862	➤ Sign Up
Brazil	PI0416743	➤ Sign Up
Canada	2545034	➤ Sign Up
China	102784386	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck

Queensland Health

Harvard Business School

Cipla

Daiichi Sankyo

Deloitte

Federal Trade Commission

Colorcon

Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.